Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for the Treatment of Hypertension
January 17 2013 - 5:00PM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) announced today that its
Canadian subsidiary, Forest Laboratories Canada Inc. has received a
Notice of Compliance from Health Canada for BYSTOLIC® (nebivolol)
tablets, a once daily beta blocker for the treatment of
hypertension.
“We are pleased that Health Canada has granted approval for
BYSTOLIC. This is an important milestone for Forest, as it is the
first product approved for our newly established Canadian
subsidiary. We look forward to bringing additional innovative
Forest products to the Canadian market,” commented David Solomon,
Senior Vice President of Corporate Development and Strategic
Planning, Forest Laboratories, Inc.
BYSTOLIC is expected to be available to Canadian patients in Q2
2013.
Forest Laboratories Canada Inc. operations are based in Toronto,
Ontario. To learn more, visit www.frx.ca.
About Forest Laboratories, Inc.
Forest Laboratories' (NYSE: FRX) longstanding global
partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective, respiratory,
gastrointestinal and pain management medicine. Forest’s pipeline,
the most robust in its history, includes product candidates in all
stages of development across a wide range of therapeutic areas. The
Company is headquartered in New York, NY. To learn more, visit
www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no obligation
to update forward-looking statements contained in this release to
reflect new information or future events or developments.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024